-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Alnylam Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2010 to 2023.
- Alnylam Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$76.9M, a 136% decline year-over-year.
- Alnylam Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$188M, a 46.9% increase year-over-year.
- Alnylam Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$282M, a 64.1% increase from 2022.
- Alnylam Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$785M, a 10.8% decline from 2021.
- Alnylam Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$709M, a 14.5% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)